ClinicalTrials.gg
CompletedNCT04902885Updated Jul 10, 2024Results posted

Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients

A Phase 3 interventional study of Trilaciclib, carboplatin, etoposide,or Topotecan and placebo, carboplatin, etoposide,or Topotecan in Extensive-stage Small-cell Lung Cancer, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-10.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Enrollment
137th of 333
95 · median 63
Started
2021
with 31 others
Phase 3
57 of 365
23 open now
Registered
126th of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 137th largest by enrollment of the 333 interventional ones that give a count, is one of 32 that started in 2021, is one of 57 in phase 3, and was the 126th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

A Randomized, double-blind, placebo-controlled, multi-center Phase 3 study evaluating efficacy, safety and pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin combined with Etoposide or Topotecan The study consists of 2 parts: Part 1: safety run-in and pharmacokinetics evaluation of 12 ES-SCLC patients (6 each for first line and second/third line ES-SCLC patients); Part 2: randomized, double-blind, placebo-controlled efficacy confirmation study of 80 ES-SCLC patients (stratified by first line and second/third line ES-SCLC, ECOG PS [0-1 vs 2] and brain metastases.

The study includes screening period, treatment period, safety follow-up and survival follow-up.

Read the detailed description

This is a multi-center Phase 3 clinical trial with an open-label single-arm safety run-in and PK evaluation part and a randomized double-blind, placebo controlled part in patients with ES-SCLC to evaluate the safety, efficacy, and pharmacokinetic profile of Trilaciclib based on completed clinical studies abroad.

The study consists of 2 parts. The first part, safety run-in and PK evaluation, enrolled approximately 12 patients with extensive-stage small-cell lung cancer, 6 patients each with 1st line ES-SCLC and 2nd/3rd line ES-SCLC to receive Trilaciclib in combination with carboplatin and etoposide (EC regimen) or with topotecan, and based on evaluable data from Cycle 1, evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy (prevention of myelosuppression) of Trilaciclib. The second part is a randomized double-blind, placebo-controlled efficacy validation study, and approximately 80 patients with ES-SCLC will be enrolled in Part II, stratified by 1st line vs 2nd/3rd line ES-SCLC, ECOG PS (0-1 vs 2), and presence vs absence of brain metastases, and randomized in a 1:1 ratio to Trilaciclib and placebo, in which patients with 1st line ES-SCLC receive Trilaciclib/placebo combined with EC regimen (Trilaciclib-EC group and placebo-EC group), and patients with 2nd/3rd line ES-SCLC receive Trilaciclib/placebo combined with topotecan (Trilaciclib-TPT group and placeboTPT group), and the efficacy of Trilaciclib (prevention of myelosuppression) will be evaluated with duration of severe neutropenia (DSN) in Cycle 1 as the primary endpoint. The planned dose of Trilaciclib is 240 mg/m2. If the safety data from the first part of the study suggest that the dose of Trilaciclib needs to be adjusted, 12 additional patients (6 patients each for 1st line ES-SCLC and 2nd/3rd line ESSCLC) will be enrolled in the first part of the study to explore the PK and safety of Trilaciclib 200 mg/m2. The study process includes screening period, treatment period, safety followup and survival follow-up.

The end of the study was defined as death in 75% of subjects, or 12 months after the last subject was enrolled, or the sponsor decided to terminate the study, whichever came first.

03

Conditions studied

  • Extensive-stage Small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years, male or female;
  2. or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC):

    • Patients scheduled to receive carboplatin plus etoposide regimen: no prior systemic therapy (eg, chemotherapy or combined with immunotherapy);
    • Patients scheduled to receive topotecan regimen: previously received 1/2 or combined immunotherapy but not topotecan.
  3. Presence of at least one radiation-naïve according to 1.1 criteria;
  4. ≥ 90 g/L;
  5. ≥ 1.5 × 10\^9/L;
  6. count ≥ 100 × 10\^9/L;
  7. Creatinine ≤ 15 mg/L or (CrCl) ≥ 60 mL/min (Cockcroft-Gault formula);
  8. Total ≤ 1.5 × (ULN);
  9. (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN or ≤ 5 × ULN (for patients with liver );
  10. Albumin ≥ 30 g/L;
  11. PS score 0 - 2;
  12. Expected survival time ≥ 3 months;
  13. :

    Females: All females of must have a negative serum pregnancy test at screening and must use reliable contraception from signing of through 3 months after the last dose; Male: Female partners of childbearing potential must use reliable contraception from signing the informed consent until 3 months after the last dose;

  14. Understand and sign informed consent

Exclusion criteria

Exclusion Criteria:

  1. Symptomatic requiring local radiotherapy or hormonal therapy;
  2. History of other , with the following exceptions: (1) clinically cured cutaneous basal cell or squamous cell tumors; (2) cured a) cervical cancer, b) prostate cancer, c) superficial bladder cancer; or (3) other solid tumors with a clinical cure time of more than 3 years;
  3. Uncontrolled ischemic heart disease or congestive heart failure ( Class III or IV);
  4. Stroke or cardiovascular or cerebrovascular event within 6 months prior to enrollment;
  5. Severe active infection;
  6. Psychological or other social factors causing insufficient trial compliance;
  7. Other uncontrolled serious chronic diseases or conditions that, in the opinion of the investigator, would make participation in the trial inappropriate;
  8. Known infection, active (defined as positive HBV DNA), and (positive HCV RNA);
  9. Radiation therapy within 2 weeks prior to enrollment;
  10. Patients who have received cytotoxic drug therapy or drug therapy within 4 weeks before enrollment, or non-cytotoxic anti-tumor drug therapy within 2 weeks;
  11. Subjects in the first part of the study should not take strong or moderate inducers of concomitantly within 4 weeks before taking the study drug, and strong inhibitors of CYP3A4 concomitantly within 2 weeks before taking the study drug;
  12. Toxicity from prior anticancer therapy has not recovered to Grade 0 or 1 (except alopecia);
  13. to the study drug (Trilaciclib, etoposide, carboplatin, topotecan) or components thereof;
  14. Persons who are unable to act independently due to legal restriction or legal sense;
  15. Pregnant or lactating women;
  16. Not suitable for participating in this study in the investigator 's opinion.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
95 participants (actual)

Study arms

  • Active comparator
    Part I ( Safety run-in and PK Evaluation); Trilaciclib Group

    12 patients( 6 patients are first line, 6 patients are second or third line) recieved Trilaciclib(240mg/m\^2) plus chemotherapy.

    Drug: Trilaciclib, carboplatin, etoposide,or Topotecan

  • Active comparator
    Part II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib Group

    41 patients received trilaciclib(240mg/m\^2) plus chemotherapy

    Drug: Trilaciclib, carboplatin, etoposide,or Topotecan

  • Placebo comparator
    Part II ( Randomized Double-blind, Placebo-controlled ), Placebo Group

    42 patients received placebo plus chemotherapy

    Drug: placebo, carboplatin, etoposide,or Topotecan

Interventions

  • Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients

    Also known as: Trilaciclib plus chemotherapy

  • Drugplacebo, carboplatin, etoposide,or Topotecan

    placebo plus carboplatin, etoposide for first line patients ;placebo plus Topotecan for second or third line patients

    Also known as: placebo plus chemotherapy

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity(AUC0-inf) for Part 1

    AUC0-inf of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.

    Time frame: Day1 and Day 3( or Day 5) of Cycle 1 for a 21-day cycle

  2. Duration of Severe Neutropenia in Cycle 1 (DSN)

    DSN in Cycle 1 was defined as the number of days from the date of the first ANC value \< 0.5 x 10\^9/L in Cycle 1 to the date of the first ANC value ≥ 0.5 x 10\^9/L. The date of the first ANC value ≥ 0.5 x 10\^9/L should meet the following requirements: (1) occurred after the ANC value was \< 0.5 x 10\^9/L, and (2) there were no other ANC values \< 0.5 x 10\^9/L between this date and the end of Cycle 1 (otherwise, if this patient entered Cycle 2, it was counted as Day 1 of Cycle 2). DSN in Cycle 1 was scored as 0 if the patient did not experience any SN during Cycle 1.

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  3. Maximum Observed Plasma Concentration(Cmax) of Trilaciclib for Part 1

    Cmax of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used. For estimation of Cmax, a concentration that was below the limit of quantification (BLQ) was assigned a value of zero if it occurred in a profile before the first measurable concentration. If a BLQ value occurred after a measurable concentration in a profile, and was followed by a value above the lower limit of quantification, then the BLQ was treated as missing data. If a BLQ value occurred at the end of the collection interval (after the last quantifiable concentration) it was treated as missing data. If two BLQ values occurred in succession after Cmax, the profile was deemed to have terminated at the first BLQ value and any subsequent concentrations were omitted.

    Time frame: Day1 and Day 3( or Day 5) of Cycle 1 for a 21-day cycle

Secondary outcomes

  1. Occurrence of Severe Neutropenia (SN)

    Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  2. Occurrence of Red Blood Cell Transfusion (on/After Week 5)

    The occurrence of RBC transfusions was defined as at least 1 cycle with RBC transfusion during the treatment period. For the treatment period, the total number of RBC transfusions was the number of cycles with RBC transfusions.

    Time frame: From week 5 to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  3. Granulocyte Colony Stimulating Factor (G-CSF) Use Rate

    Administration of G-CSF was collected with concomitant medications, which were coded using World Health Organization Drug Dictionary (WHO-DD) . A cycle where G-CSF was administered concurrently was identified by comparing the start and stop dates of each administration of G-CSF to the start of cycle and end of cycle. The occurrence of G-CSF administrations was defined as at least 1 cycle with G-CSF administrations during the treatment period. For the treatment period, the total number of G-CSF administrations was the number of cycles with G-CSF administrations.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  4. Composite Endpoints-major Hematologic AEs (Anyone of the Followings): All-cause Hospitalization; All-cause Dose Reductions; Febrile Neutropenia; SN Prolongation (Lasting > 5 Days); Red Blood Cell (RBC) Transfusions Were Performed on/After Week 5.

    MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelopreservation into a single endpoint. The individual components for MAHE were hospitalization for a hematologic event, febrile neutropenia, death related to treatment, dose delay/reduction due to ANC or platelet counts, prolonged severe neutropenia (duration \>5 days), RBC transfusion (actual or eligible) and platelet transfusion (actual or eligible). Event rate per week, calculated as the total number of events divided by duration of in weeks.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  5. Occurrence of Grade 3 and 4 Hematological Toxicities

    Occurrence of Grade 3 and 4 hematological toxicities was defined according to CTCAE 5.0 during the treatment period.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  6. Erythropoiesis Stimulating Agent (ESA) Use Rate

    Administration of ESA was collected with concomitant medications, which were coded using WHO-DD . A cycle where an ESA was administered concurrently was identified by comparing the start and stop dates of each administration of an ESA to the start of cycle and end of cycle. The occurrence of ESA administration was at least 1 cycle with an ESA administration during the treatment period. For the treatment period, the total number of ESA administrations was the number of cycles with ESA administrations.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  7. Recombinant Human Interleukin-11 Use Rate

    Administration of interleukin-11 was collected with concomitant medications, which were coded using WHO-DD Version. A cycle where interleukin-11 was administered concurrently was identified by comparing the start and stop dates of each administration of interleukin-11 to the start of cycle and end of cycle. The occurrence of interleukin-11 administration was at least 1 cycle with interleukin-11 administration during the treatment period.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  8. Thrombopoietin (TPO) Use Rate

    Administration of TPO was collected with concomitant medications, which were coded using WHO-DD Version. A cycle where TPO was administered concurrently was identified by comparing the start and stop dates of each administration of TPO to the start of cycle and end of cycle. The occurrence of TPO administration was at least 1 cycle with TPO administration during the treatment period.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  9. Occurrence of Intravenous or Oral Antibiotic Administration

    Administration of intravenous or oral antibiotic was collected with concomitant medications, which were coded using WHO-DD Version. A cycle where intravenous or oral antibiotic was administered concurrently was identified by comparing the start and stop dates of each administration of intravenous or oral antibiotic to the start of cycle and end of cycle. The occurrence of intravenous or oral antibiotic administration was at least 1 cycle with intravenous or oral antibiotic administration during the treatment period.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  10. Occurrence of Infectious Serious Adverse Events

    SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. An infectious SAE was a serious event in the Medical Dictionary for Regulatory Activities (MedDRA) system organ class "infections and infestations" and a preferred term of anal abscess, bacteraemia, bronchitis, candida infection, chronic sinusitis, conjunctivitis, infection, influenza, nasopharyngitis, oral candidiasis, oral herpes, pharyngitis streptococcal, pneumonia, pneumonia bacterial, respiratory tract infection, sepsis, skin infection, upper respiratory tract infection, urinary tract infection, urosepsis or viral upper respiratory tract infection.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  11. Occurrence of Lung Infection SAEs

    SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. A lung infection SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of bronchitis, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, upper respiratory tract infection or viral upper respiratory tract infection.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  12. Occurrence of Febrile Neutropenia

    Each febrile neutropenia event (as defined by Common Terminology Criteria for Adverse Events \[CTCAE\]) was captured as an AE. The occurrence of febrile neutropenia was defined as at least 1 febrile neutropenia event during the treatment period. For the treatment period, the total number of febrile neutropenia events was the number of febrile neutropenia events with a unique start date.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  13. Occurrence of Platelet Transfusion

    The occurrence of platelet transfusions was defined as at least 1 cycle with platelet transfusion during the treatment period. For the treatment period, the total number of platelet transfusions was the number of cycles with platelet transfusions.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months

  14. Objective Tumor Response Rate (ORR)

    ORR was performed based on the Response Evaluation Analysis Set (RES). Based on the assessments at each visit, the number and percentage of patients with best response of CR, PR, SD, PD and NE will be summarized by treatment group when CR/PR confirmation is not required and CR/PR confirmation is required, respectively . In particular, SD BOR requires at least 35 days or more after enrollment.ORR was calculated based on the number of patients with best response of CR or PR.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 18 months

  15. Disease Control Rate (DCR)

    DCR was performed based on the Response Evaluation Analysis Set (RES). Based on the assessments at each visit, the number and percentage of patients with best response of CR, PR, SD, PD and NE will be summarized by treatment group when CR/PR confirmation is not required and CR/PR confirmation is required, respectively . In particular, SD BOR requires at least 35 days or more after enrollment. DCR was calculated based on the number of patients with best response of CR PR or SD.

    Time frame: From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 18 months

07

Results

Posted Jul 10, 2024

Participant flow

For Part 1, participants were recruited based on physician referral at 4 academic medical centers ,and the first participant was enrolled on May 25, 2021 and the last participant was enrolled in July 20 2021. For Part 2, participants were recruited based on physician referral at 20 academic medical centers ,and the first participant was enrolled in August 20, 2021 and the last participant was enrolled in December 1 2021.

Participant flow — Overall Study
MilestonePart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Started124142
Completed124142
Not completed000

Outcome measures

PrimaryArea Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity(AUC0-inf) for Part 1

AUC0-inf of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.

Time frame:
Day1 and Day 3( or Day 5) of Cycle 1 for a 21-day cycle
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity(AUC0-inf) for Part 1
h*ng/mLPart I ( Safety run-in and PK Evaluation); Trilaciclib Group, First Line ES-SCLCPart I ( Safety run-in and PK Evaluation); Trilaciclib Group, Second or Third Line ES-SCLC
Day 1 Cycle 12200 ± 14.52598 ± 23.5
first line: Day 3 Cycle 1 Second or third line: Day 5 Cycle 12878 ± 38.62675 ± 22.0
PrimaryDuration of Severe Neutropenia in Cycle 1 (DSN)

DSN in Cycle 1 was defined as the number of days from the date of the first ANC value \< 0.5 x 10\^9/L in Cycle 1 to the date of the first ANC value ≥ 0.5 x 10\^9/L. The date of the first ANC value ≥ 0.5 x 10\^9/L should meet the following requirements: (1) occurred after the ANC value was \< 0.5 x 10\^9/L, and (2) there were no other ANC values \< 0.5 x 10\^9/L between this date and the end of Cycle 1 (otherwise, if this patient entered Cycle 2, it was counted as Day 1 of Cycle 2). DSN in Cycle 1 was scored as 0 if the patient did not experience any SN during Cycle 1.

Time frame:
At the end of Cycle 1 (each cycle is 21 days)
Reported as:
Mean · Days
Duration of Severe Neutropenia in Cycle 1 (DSN)
DaysPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Duration of Severe Neutropenia in Cycle 1 (DSN)0.7 ± 2.310 ± 1.72 ± 3.0
Statistical analysis
  • Part II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib Group vs Part II ( Randomized Double-blind, Placebo-controlled ), Placebo Group · non-parametric ANCOVA · p = 0.0003
PrimaryMaximum Observed Plasma Concentration(Cmax) of Trilaciclib for Part 1

Cmax of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used. For estimation of Cmax, a concentration that was below the limit of quantification (BLQ) was assigned a value of zero if it occurred in a profile before the first measurable concentration. If a BLQ value occurred after a measurable concentration in a profile, and was followed by a value above the lower limit of quantification, then the BLQ was treated as missing data. If a BLQ value occurred at the end of the collection interval (after the last quantifiable concentration) it was treated as missing data. If two BLQ values occurred in succession after Cmax, the profile was deemed to have terminated at the first BLQ value and any subsequent concentrations were omitted.

Time frame:
Day1 and Day 3( or Day 5) of Cycle 1 for a 21-day cycle
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration(Cmax) of Trilaciclib for Part 1
ng/mLPart I ( Safety run-in and PK Evaluation); Trilaciclib Group, First Line ES-SCLCPart I ( Safety run-in and PK Evaluation); Trilaciclib Group, Second or Third Line ES-SCLC
Day 1 Cycle 11007 ± 18.8918 ± 46.7
First line: Day 3 Cycle 1 Second or third line: Day 5 Cycle 1893 ± 36.2776 ± 29.9
SecondaryOccurrence of Severe Neutropenia (SN)

Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Occurrence of Severe Neutropenia (SN)
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Occurrence of Severe Neutropenia (SN)2420
SecondaryOccurrence of Red Blood Cell Transfusion (on/After Week 5)

The occurrence of RBC transfusions was defined as at least 1 cycle with RBC transfusion during the treatment period. For the treatment period, the total number of RBC transfusions was the number of cycles with RBC transfusions.

Time frame:
From week 5 to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Occurrence of Red Blood Cell Transfusion (on/After Week 5)
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Occurrence of Red Blood Cell Transfusion (on/After Week 5)022
SecondaryGranulocyte Colony Stimulating Factor (G-CSF) Use Rate

Administration of G-CSF was collected with concomitant medications, which were coded using World Health Organization Drug Dictionary (WHO-DD) . A cycle where G-CSF was administered concurrently was identified by comparing the start and stop dates of each administration of G-CSF to the start of cycle and end of cycle. The occurrence of G-CSF administrations was defined as at least 1 cycle with G-CSF administrations during the treatment period. For the treatment period, the total number of G-CSF administrations was the number of cycles with G-CSF administrations.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Granulocyte Colony Stimulating Factor (G-CSF) Use Rate
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Granulocyte Colony Stimulating Factor (G-CSF) Use Rate42829
SecondaryComposite Endpoints-major Hematologic AEs (Anyone of the Followings): All-cause Hospitalization; All-cause Dose Reductions; Febrile Neutropenia; SN Prolongation (Lasting > 5 Days); Red Blood Cell (RBC) Transfusions Were Performed on/After Week 5.

MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelopreservation into a single endpoint. The individual components for MAHE were hospitalization for a hematologic event, febrile neutropenia, death related to treatment, dose delay/reduction due to ANC or platelet counts, prolonged severe neutropenia (duration \>5 days), RBC transfusion (actual or eligible) and platelet transfusion (actual or eligible). Event rate per week, calculated as the total number of events divided by duration of in weeks.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Number · events per week
Composite Endpoints-major Hematologic AEs (Anyone of the Followings): All-cause Hospitalization; All-cause Dose Reductions; Febrile Neutropenia; SN Prolongation (Lasting > 5 Days); Red Blood Cell (RBC) Transfusions Were Performed on/After Week 5.
events per weekPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Composite Endpoints-major Hematologic AEs (Anyone of the Followings): All-cause Hospitalization; All-cause Dose Reductions; Febrile Neutropenia; SN Prolongation (Lasting > 5 Days); Red Blood Cell (RBC) Transfusions Were Performed on/After Week 5.0.0330.0400.077
SecondaryOccurrence of Grade 3 and 4 Hematological Toxicities

Occurrence of Grade 3 and 4 hematological toxicities was defined according to CTCAE 5.0 during the treatment period.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Occurrence of Grade 3 and 4 Hematological Toxicities
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Occurrence of Grade 3 and 4 Hematological Toxicities62438
SecondaryErythropoiesis Stimulating Agent (ESA) Use Rate

Administration of ESA was collected with concomitant medications, which were coded using WHO-DD . A cycle where an ESA was administered concurrently was identified by comparing the start and stop dates of each administration of an ESA to the start of cycle and end of cycle. The occurrence of ESA administration was at least 1 cycle with an ESA administration during the treatment period. For the treatment period, the total number of ESA administrations was the number of cycles with ESA administrations.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Erythropoiesis Stimulating Agent (ESA) Use Rate
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Erythropoiesis Stimulating Agent (ESA) Use Rate168
SecondaryRecombinant Human Interleukin-11 Use Rate

Administration of interleukin-11 was collected with concomitant medications, which were coded using WHO-DD Version. A cycle where interleukin-11 was administered concurrently was identified by comparing the start and stop dates of each administration of interleukin-11 to the start of cycle and end of cycle. The occurrence of interleukin-11 administration was at least 1 cycle with interleukin-11 administration during the treatment period.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Recombinant Human Interleukin-11 Use Rate
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Recombinant Human Interleukin-11 Use Rate21211
SecondaryThrombopoietin (TPO) Use Rate

Administration of TPO was collected with concomitant medications, which were coded using WHO-DD Version. A cycle where TPO was administered concurrently was identified by comparing the start and stop dates of each administration of TPO to the start of cycle and end of cycle. The occurrence of TPO administration was at least 1 cycle with TPO administration during the treatment period.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Thrombopoietin (TPO) Use Rate
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Thrombopoietin (TPO) Use Rate41010
SecondaryOccurrence of Intravenous or Oral Antibiotic Administration

Administration of intravenous or oral antibiotic was collected with concomitant medications, which were coded using WHO-DD Version. A cycle where intravenous or oral antibiotic was administered concurrently was identified by comparing the start and stop dates of each administration of intravenous or oral antibiotic to the start of cycle and end of cycle. The occurrence of intravenous or oral antibiotic administration was at least 1 cycle with intravenous or oral antibiotic administration during the treatment period.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Occurrence of Intravenous or Oral Antibiotic Administration
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Occurrence of Intravenous or Oral Antibiotic Administration31113
SecondaryOccurrence of Infectious Serious Adverse Events

SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. An infectious SAE was a serious event in the Medical Dictionary for Regulatory Activities (MedDRA) system organ class "infections and infestations" and a preferred term of anal abscess, bacteraemia, bronchitis, candida infection, chronic sinusitis, conjunctivitis, infection, influenza, nasopharyngitis, oral candidiasis, oral herpes, pharyngitis streptococcal, pneumonia, pneumonia bacterial, respiratory tract infection, sepsis, skin infection, upper respiratory tract infection, urinary tract infection, urosepsis or viral upper respiratory tract infection.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Occurrence of Infectious Serious Adverse Events
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Occurrence of Infectious Serious Adverse Events010
SecondaryOccurrence of Lung Infection SAEs

SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. A lung infection SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of bronchitis, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, upper respiratory tract infection or viral upper respiratory tract infection.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Occurrence of Lung Infection SAEs
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Occurrence of Lung Infection SAEs010
SecondaryOccurrence of Febrile Neutropenia

Each febrile neutropenia event (as defined by Common Terminology Criteria for Adverse Events \[CTCAE\]) was captured as an AE. The occurrence of febrile neutropenia was defined as at least 1 febrile neutropenia event during the treatment period. For the treatment period, the total number of febrile neutropenia events was the number of febrile neutropenia events with a unique start date.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Occurrence of Febrile Neutropenia
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Occurrence of Febrile Neutropenia117
SecondaryOccurrence of Platelet Transfusion

The occurrence of platelet transfusions was defined as at least 1 cycle with platelet transfusion during the treatment period. For the treatment period, the total number of platelet transfusions was the number of cycles with platelet transfusions.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 12 months
Reported as:
Count of participants · Participants
Occurrence of Platelet Transfusion
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Occurrence of Platelet Transfusion034
SecondaryObjective Tumor Response Rate (ORR)

ORR was performed based on the Response Evaluation Analysis Set (RES). Based on the assessments at each visit, the number and percentage of patients with best response of CR, PR, SD, PD and NE will be summarized by treatment group when CR/PR confirmation is not required and CR/PR confirmation is required, respectively . In particular, SD BOR requires at least 35 days or more after enrollment.ORR was calculated based on the number of patients with best response of CR or PR.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 18 months
Reported as:
Count of participants · Participants
Objective Tumor Response Rate (ORR)
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Objective Tumor Response Rate (ORR)21715
SecondaryDisease Control Rate (DCR)

DCR was performed based on the Response Evaluation Analysis Set (RES). Based on the assessments at each visit, the number and percentage of patients with best response of CR, PR, SD, PD and NE will be summarized by treatment group when CR/PR confirmation is not required and CR/PR confirmation is required, respectively . In particular, SD BOR requires at least 35 days or more after enrollment. DCR was calculated based on the number of patients with best response of CR PR or SD.

Time frame:
From date of randomization , 21 day treatment cycle to the end of the treatment until (if earlier) disease progression, start of subsequent anticancer treatment, withdrawal of informed consent, or death, acessed up to a maximum of 18 months
Reported as:
Count of participants · Participants
Disease Control Rate (DCR)
ParticipantsPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Disease Control Rate (DCR)83231

Adverse events

Collected over Adverse events were monitored from the time of informed consent through the end of the safety follow-up period, initiation of new antineoplastic therapy, or withdrawal from the study, whichever came first, acessed up to a maximum of 18 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part I ( Safety run-in and PK Evaluation); Trilaciclib Group6/12 (50%)4/12 (33.3%)12/12 (100%)
Part II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib Group22/41 (53.7%)12/41 (29.3%)41/41 (100%)
Part II ( Randomized Double-blind, Placebo-controlled ), Placebo Group28/42 (66.7%)15/42 (35.7%)42/42 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
Platelet count decreasedInvestigations1/125/416/42
Neutrophil count decreasedInvestigations1/122/415/42
Oxygen saturation decreasedInvestigations1/120/410/42
acute cardiac failureCardiac disorders1/120/410/42
Febrile neutropeniaBlood and lymphatic system disorders0/121/413/42
AnaemiaBlood and lymphatic system disorders0/122/412/42
DeathGeneral disorders0/120/412/42
White blood cell count decreasedInvestigations0/121/412/42
PyrexiaGeneral disorders0/121/410/42
Type 2 diabetes mellitusMetabolism and nutrition disorders0/121/410/42
Most frequent other events
Showing 10 of 71
Most frequent other events
EventPart I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo Group
White blood cell count decreasedInvestigations7/1232/4142/42
Neutrophil count decreasedInvestigations7/1233/4140/42
AnaemiaBlood and lymphatic system disorders8/1228/4135/42
Platelet count decreasedInvestigations6/1228/4134/42
HypertriglyceridaemiaMetabolism and nutrition disorders7/1212/419/42
ConstipationGastrointestinal disorders0/1213/4118/42
Alanine aminotransferase increasedInvestigations5/1211/4112/42
NauseaGastrointestinal disorders5/1213/4114/42
decreased appetiteMetabolism and nutrition disorders5/126/4113/42
Aspartate aminotransferase increasedInvestigations4/128/4110/42

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo GroupTotal
Mean61.1 ± 7.0662.0 ± 7.7859.4 ± 8.7160.7 ± 8.13
Sex: Female, Male
Sex: Female, Male(Participants)Part I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo GroupTotal
Female9333577
Male38718
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo GroupTotal
American Indian or Alaska Native0000
Asian12414295
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Part I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo GroupTotal
China12414295
Brain metastases at baseline
Brain metastases at baseline(participants)Part I ( Safety run-in and PK Evaluation); Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib GroupPart II ( Randomized Double-blind, Placebo-controlled ), Placebo GroupTotal
Number5131634
08

Study locations

1 site
  • Jilin Cancer Hopspital
    Changchun, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Dec 2021, 7 months.

Results were first posted in Jul 2024, 2 years 6 months after primary completion.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 7 months is below that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2021
First posted
May 26, 2021
StartActual
May 25, 2021
Primary completionActual
Dec 29, 2021
CompletionActual
Dec 31, 2022
Results first posted
Jul 10, 2024
Last update
Jul 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04902885
Responsible party
Sponsor
First posted
May 26, 2021
Start date
May 25, 2021
Primary completion
Dec 29, 2021
Completion
Dec 31, 2022
Results posted
Jul 10, 2024
Last update
Jul 10, 2024

Study contacts

Ying Cheng, Doctor
principal investigator · Jilin Provincial Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trilaciclib

Start the discussion